NCT03226821View on ClinicalTrials.gov

Body Composition and Adipose Tissue in HIV

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
HIV Lipodystrophy SyndromeGrowth Hormone DeficiencyBody Composition
Interventions
DRUG

Tesamorelin

Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

Trial Locations (1)

10032

Neuroendocrine Unit and Pituitary Center, Columbia University, New York

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Columbia University

OTHER

NCT03226821 - Body Composition and Adipose Tissue in HIV | Biotech Hunter | Biotech Hunter